Sands Capital Life Sciences Pulse Fund II, L.P. - 30 Jun 2025 SCHEDULE 13G/A Report for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share (IKT)

Filing Manager
Sands Capital Life Sciences Pulse Fund II, L.P.
Reporting Manager
Sands Capital Life Sciences Pulse Fund II, L.P.
Security
Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share
Symbol
IKT
Shares outstanding
74,489,796 shares
Disclosed Ownership
10,950,000 shares
Ownership
15%
Form type
SCHEDULE 13G/A
Filing time
13 Aug 2025, 11:17:42 UTC
Date of event
30 Jun 2025
SEC
View on sec.gov

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Sands Capital Life Sciences Pulse Fund II, L.P. 15% 10,950,000 0 10,950,000 /s/ Jonathan Goodman Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P.
Sands Capital Alternatives, LLC 15% 10,950,000 0 10,950,000 /s/ Jonathan Goodman Jonathan Goodman, General Counsel
SANDS FRANK M. 15% 10,950,000 0 10,950,000 /s/ Frank M. Sands Frank M. Sands